The UK approach to COVID-19 vaccination: why was it so different?

The vaccination campaign in the United Kingdom has been extremely successful. Bold decisions were made to order vaccines early, before we knew if they would be effective, and to vary from the manufacturers’ recommendations by extending the ‘prime-boost’ interval between the first and second doses of...

Descripción completa

Detalles Bibliográficos
Autor principal: English, Peter MB
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152776/
https://www.ncbi.nlm.nih.gov/pubmed/34104199
http://dx.doi.org/10.7573/dic.2021-4-5
_version_ 1783698667317755904
author English, Peter MB
author_facet English, Peter MB
author_sort English, Peter MB
collection PubMed
description The vaccination campaign in the United Kingdom has been extremely successful. Bold decisions were made to order vaccines early, before we knew if they would be effective, and to vary from the manufacturers’ recommendations by extending the ‘prime-boost’ interval between the first and second doses of the AstraZeneca and Pfizer-BioNTech vaccines. These decisions were controversial at the time but have contributed enormously to the effectiveness of the vaccination programme. This is a personal perspective on the approach to COVID-19 vaccination in the United Kingdom.
format Online
Article
Text
id pubmed-8152776
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioExcel Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-81527762021-06-07 The UK approach to COVID-19 vaccination: why was it so different? English, Peter MB Drugs Context Commentary The vaccination campaign in the United Kingdom has been extremely successful. Bold decisions were made to order vaccines early, before we knew if they would be effective, and to vary from the manufacturers’ recommendations by extending the ‘prime-boost’ interval between the first and second doses of the AstraZeneca and Pfizer-BioNTech vaccines. These decisions were controversial at the time but have contributed enormously to the effectiveness of the vaccination programme. This is a personal perspective on the approach to COVID-19 vaccination in the United Kingdom. BioExcel Publishing Ltd 2021-05-25 /pmc/articles/PMC8152776/ /pubmed/34104199 http://dx.doi.org/10.7573/dic.2021-4-5 Text en Copyright © 2021 English PMB. https://creativecommons.org/licenses/by-nc-nd/4.0/Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
spellingShingle Commentary
English, Peter MB
The UK approach to COVID-19 vaccination: why was it so different?
title The UK approach to COVID-19 vaccination: why was it so different?
title_full The UK approach to COVID-19 vaccination: why was it so different?
title_fullStr The UK approach to COVID-19 vaccination: why was it so different?
title_full_unstemmed The UK approach to COVID-19 vaccination: why was it so different?
title_short The UK approach to COVID-19 vaccination: why was it so different?
title_sort uk approach to covid-19 vaccination: why was it so different?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152776/
https://www.ncbi.nlm.nih.gov/pubmed/34104199
http://dx.doi.org/10.7573/dic.2021-4-5
work_keys_str_mv AT englishpetermb theukapproachtocovid19vaccinationwhywasitsodifferent
AT englishpetermb ukapproachtocovid19vaccinationwhywasitsodifferent

Ejemplares similares